Ab­b­Vie stirs safe­ty jit­ters af­ter two pa­tients die in ABT-494 study

Ab­b­Vie $AB­BV re­vealed that two rheuma­toid arthri­tis pa­tients died in its late-stage work on ABT-494, which quick­ly trig­gered a case of the jit­ters for a drug tout­ed as a ma­jor part of the com­pa­ny’s late-stage pipeline hopes.

Ac­cord­ing to re­searchers, the two pa­tient deaths in­clude one for un­known caus­es. A sec­ond pa­tient in the 30 mg dose group came down with a fever and had prob­lems with di­ar­rhea. The sub­ject sub­se­quent­ly ex­pe­ri­enced heart fail­ure and pre­sumed pul­monary em­bolism.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.